-
121.发明授权公开(公告)号：US10572999B2
公开(公告)日：2020-02-25
申请号：US15843708
申请日：2017-12-15
Applicant: Wake Forest University Health Sciences
Inventor： Youngkyoo Jung
Abstract: Methods, systems, computer programs, circuits and workstations are configured to generate at least one two-dimensional weighted CBF territory map of color-coded source artery locations using an automated vascular segmentation process to identify source locations using mutual connectivity in both image and label space.
-
公开(公告)号：US20190382336A1
公开(公告)日：2019-12-19
申请号：US16550967
申请日：2019-08-26
Inventor： W. Todd Lowther , Ross P. Holmes , Daniel Yohannes
IPC: C07C229/48 , C07C59/11 , C07C62/24 , C07C62/02 , C07D307/68 , C07D307/24 , C07D233/90 , C07D333/38
Abstract: Provided herein are compounds of Formula I, Formula II, and Formula III, and compositions comprising the same, as well as methods of use thereof for controlling or inhibiting the formation of calcium oxalate kidney stones, inhibiting the production of glyoxylate and/or oxalate, and/or inhibiting hydroxyproline dehydrogenase (HYPDH).
-
公开(公告)号：US20190209695A1
公开(公告)日：2019-07-11
申请号：US16166875
申请日：2018-10-22
Applicant: Wake Forest University Health Sciences
Inventor： William H. Gmeiner
IPC: A61K47/54 , A61K31/704 , A61K31/7072 , C12N15/10
CPC classification number: A61K47/549 , A61K31/337 , A61K31/704 , A61K31/7048 , A61K31/7072 , A61K47/548 , C12N15/1048 , C12N15/115 , C12N2310/16 , C12N2310/351
Abstract: Provided herein are aptamers and pharmaceutical compositions comprising the same. In some embodiments, the aptamer selectively binds a protein of interest such as an extracellular receptor protein of interest (e.g., a cancer cell extracellular receptor protein, which may be differentially expressed in some embodiments). In some embodiments, the aptamer is directly linked by covalent bonding (e.g., via a geminal diamine linkage) to from 2 to 10 toxin compounds. Also provided herein is a method of selecting an aptamer that specifically binds to a protein expressed by a cell of interest, wherein in some embodiments the aptamer comprises at least one binding site for one or more active compounds. In some embodiments, primer regions flanking the variable region of the aptamers in the pool contains from 1 to 10 mismatches with respect to said forward or reverse primer.
-
公开(公告)号：US20190203038A1
公开(公告)日：2019-07-04
申请号：US16263222
申请日：2019-01-31
Applicant: WAKE FOREST UNIVERSITY HEALTH SCIENCES
Inventor： Carlos Kengla
IPC: C08L67/04 , C08K3/32 , B29C64/118 , B29C64/205 , A61L27/46 , A61L27/38 , A61L27/58 , A61L27/56
CPC classification number: C08L67/04 , A61L27/3847 , A61L27/46 , A61L27/56 , A61L27/58 , A61L2430/02 , B29C64/118 , B29C64/205 , B29K2067/04 , B29K2509/02 , C08K3/32 , C08K2003/325
Abstract: Provided herein are improved compositions and methods of making and using the same, the composition comprising a polymer and a ceramic present at a ratio of from 3:1 to 1:3 of polymer:ceramic by weight, wherein the composition comprises or is a composite of the polymer and the ceramic having improved printability and/or having an improved elastic modulus and/or improved stress at failure (e.g., as compared to a blend of the polymer and the ceramic). Improved medical implants incorporating the same are also provided.
-
公开(公告)号：US20190153382A1
公开(公告)日：2019-05-23
申请号：US16227690
申请日：2018-12-20
Applicant: WAKE FOREST UNIVERSITY HEALTH SCIENCES
Inventor： James Yoo , Tao Xu , Anthony Atala
Abstract: A method of forming an array of viable cells is carried out by ink-jet printing a cellular composition containing said cells on a substrate. At least two different types of viable mammalian cells are printed on the substrate, the at least two different types of viable mammalian cells selected to together form a tissue. In some embodiments at least three or four different viable mammalian cells are printed on the substrate, the cells selected to together form a tissue. In some embodiments one of the viable mammalian cell types is a stem cell. In some embodiments the method further comprises printing at least one support compound on the substrate, the support compound selected to form a tissue together with said cells. In some embodiments the method further comprises printing at least one growth factor on the substrate, the growth factor selected to cause the cells to form a tissue.
-
Patent Agency Ranking
公开(公告)号：US20190127884A1
公开(公告)日：2019-05-02
申请号：US16171504
申请日：2018-10-26
Applicant: Wake Forest University Health Sciences
Inventor： Sang Jin Lee , James J. Yoo , Young Min Ju , Anthony Atala
IPC: D01D5/00 , A61K35/44 , C07K16/46 , A61L27/24 , A61K31/737 , A61K38/36 , A61K31/728 , A61K31/729 , A61K38/39 , C07K16/28 , C07D315/00 , A61K38/18
Abstract: The invention is directed to products and methods for preparing self-seeding vascular constructs generated as a bi-layered electrospun matrices, conjugated with EPC-specific antibodies and anti-thrombogenic agents on the inner surfaces of their lumens.
-
公开(公告)号：US10272088B2
公开(公告)日：2019-04-30
申请号：US15328797
申请日：2015-07-25
Applicant: Wake Forest University Health Sciences
Inventor： Aaron M. Mohs , Steve J. Kridel , Tanner K. Hill
IPC: A61K31/519 , A61K31/085 , A61K31/336 , A61K31/341 , A61K31/352 , A61K31/365 , A61K31/4965 , A61K45/06 , A61K9/51 , A61K47/61 , A61K47/69 , A61K31/353 , A61K31/366
Abstract: The present invention relates to compounds, compositions and methods comprising nanoparticles (NP) that are based on hyaluronic acid (HLA) that have been modified with hydrophobic moieties that can entrap FASN inhibitor compounds. In one embodiment, the FASN inhibitor compounds include Orlistat. In one embodiment, the hydrophobic moieties comprise 5-βCA, Pba, or ODA, or combinations thereof. In a variation, the present invention relates to a composition comprising NPs based upon HLA, Orlistat, one or more of the hydrophobic moieties comprising 5-βCA, Pba, or ODA, and one or more of members selected from the group consisting of PEG and a dilute solution containing SDS.
-
128.发明申请公开(公告)号：US20190112660A1
公开(公告)日：2019-04-18
申请号：US16088359
申请日：2017-03-24
Applicant: Arthur KRIGSMAN , WAKE FOREST UNIVERSITY HEALTH SCIENCES
Inventor： Arthur KRIGSMAN , Stephen WALKER
IPC: C12Q1/6883 , G01N33/68
Abstract: The invention provides compositions and methods for identifying autism and autism spectrum disorders in humans. The invention also includes compositions and methods for identifying unique blood-based gene expression profiles in children with regressive autism spectrum disorder (ASD) and ileocolitis.
-
公开(公告)号：US20190106673A1
公开(公告)日：2019-04-11
申请号：US16156535
申请日：2018-10-10
Applicant: Wake Forest University Health Sciences
Inventor： Aleksander Skardal
Abstract: Described herein are bioink compositions, which may have an elastic modulus similar to a natural tissue and/or tunable mechanical properties, along with methods of preparing and using the compositions. The compositions described herein may be useful as a medium for cell and/or tissue culture and/or for bioprinting, but are not limited thereto.
-
公开(公告)号：US10251915B2
公开(公告)日：2019-04-09
申请号：US15689268
申请日：2017-08-29
Applicant: Wake Forest University Health Sciences
Inventor： Emmanuel C. Opara , Benjamin S. Harrison
IPC: A61K35/39 , C12N5/071 , A61K45/06 , A61K9/50 , A61K9/00 , A61K47/22 , A61K38/18 , A61K47/02 , A61K47/42 , A61K38/44 , A61K31/555 , A61K33/40 , C12N1/04 , C12N11/10 , C12N11/04
Abstract: Microcapsules are described that comprise (a) a liquid aqueous or hydrogel core; (b) a semipermeable membrane surrounding said core; (c) live animal cells (e.g., pancreatic cells) in the core; and (d) oxygen-generating particles in said core, said oxygen-generating particles included in said microcapsules in an amount sufficient to lengthen the duration of viability of said animal cells in said microcapsules. Compositions comprising such microcapsules and uses thereof, such as in treating diabetes, are also described.
-
-
-
-
-
-
-
-
-
Search Results
514
records
(took 0.035 seconds)
